Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Nektar, AMD, Esperion, and More: Here’s Why These Five Stocks Are Surging

Page 1 of 2

Although the broader markets are relatively calm, five stocks, Nektar Therapeutics (NASDAQ:NKTR), Advanced Micro Devices, Inc. (NASDAQ:AMD), Esperion Therapeutics Inc (NASDAQ:ESPR), Alibaba Group Holding Ltd (NYSE:BABA), and Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZare each surging for various reasons. In this article, let’s uncover why traders are buying and analyze smart money sentiment toward them.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

Wall Street Bull

Wall Street Bull

Nektar Therapeutics (NASDAQ:NKTR) shares are 28% in the green after the company reported that opioid analgesic NKTR-181 met both primary and secondary endpoints in a phase 3 study for patients with moderate to severe chronic pain. The FDA has granted NKTR-181 its fast track designation for the treatment of moderate to severe chronic pain. Martin Hale, M.D., medical director of Gold Coast Research, said, ‘The data from this efficacy study are extremely important because they demonstrate that NKTR-181 produces strong analgesia in patients suffering from chronic pain while NKTR-181 has also demonstrated significantly lower abuse potential than oxycodone in a human abuse potential study’. Full data from the phase 3 study will be presented at a medical meeting in the second half of 2017. Of the 742 elite funds we track, 16 funds owned $152.96 million of Nektar Therapeutics (NASDAQ:NKTR) and accounted for 8.10% of the float on December 31, versus 17 funds and $222.31 million respectively on September 30.

Follow Nektar Therapeutics (NASDAQ:NKTR)
Trade (NASDAQ:NKTR) Now!

Advanced Micro Devices, Inc. (NASDAQ:AMD) has surged 6.3% after Mark Lipacis of Jefferies upped his price target on the semi-conductor maker to $16 from $13, citing improved visibility for the company’s launch of the Ryzen 5 and Ryzen 7 processor. Given that product launch, the analyst thinks AMD will gain ‘meaningful’ market share versus Intel in the Server, Desktop, and Notebook segments this year. 32 top funds had a bullish position in Advanced Micro Devices, Inc. (NASDAQ:AMD) at the end of the fourth quarter, down 15 funds from the previous quarter.

Follow Advanced Micro Devices Inc (NASDAQ:AMD)
Trade (NASDAQ:AMD) Now!

On the next page, we examine Esperion Therapeutics Inc, Alibaba Group Holding Ltd, and Jazz Pharmaceuticals plc – Ordinary Shares.
Page 1 of 2
Loading...